Navigation Links
Estrogen-lowering drugs minimize surgery in breast cancer patients
Date:5/20/2010

A nationwide study has confirmed the benefit of giving estrogen-lowering drugs before surgery to breast cancer patients. The treatment increased the likelihood that women could undergo breast-conservation surgery, also called lumpectomy, instead of mastectomy.

The study's chair, Matthew J. Ellis, MD, PhD, the Anheuser-Busch Endowed Chair in Medical Oncology and a breast cancer specialist with the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, will present the findings June 7 at the annual meeting of the American Society of Clinical Oncology.

Sponsored by the American College of Surgeons Oncology Group, the study took place at 118 hospitals across the country and involved 352 postmenopausal women with estrogen-receptor positive (ER+) breast tumors. The participants received aromatase inhibitors for 16 weeks before surgery for breast cancer, and the extent of their tumors was monitored before and after the drug treatment.

The lead investigator at the Washington University site was Julie A. Margenthaler, MD, assistant professor of surgery and a breast surgeon at the Siteman Cancer Center.

Aromatase inhibitors are also referred to as estrogen-lowering agents because they interfere with the body's production of estrogen, a hormone that stimulates the growth of ER+ breast tumors. ER+ is the most common breast cancer, accounting for three-quarters of cases.

All women in the study had stage II or III breast cancer, in which tumors are about an inch or larger in size and may have spread to the lymph nodes in the underarm area. Participants were placed in one of three groups at the study's start:

  • marginal, meaning breast-conservation surgery was possible but likely to be disfiguring or to require several surgical procedures;
  • mastectomy-only, meaning breast-conservation surgery was not possible; and
  • inoperable, meaning mastectomy would not completely remove the cancer.

After the 16-week aromatase inhibitor therapy, the women were reevaluated to see which surgical option was appropriate for them. The results showed that 82 percent of women in the marginal group, 51 percent in the mastectomy-only group and 75 percent in the inoperable group had successful breast-conservation surgery instead of mastectomy.

"Aromatase inhibitor therapy shrank the tumors in many of these women and improved surgical outcomes," Ellis says. "These results will encourage a change in practice across the country so that more women can benefit from the currently underutilized approach of administering estrogen-lowering agents before surgery."

The study participants were randomly assigned to receive one of three estrogen-lowering agents: exemestane (25 mg daily), letrozole (2.5 mg daily) or anastrozole (1 mg daily). No statistically significant difference in effectiveness was found among the three drugs.

Ellis explains that there are other benefits to using estrogen-lowering agents before surgery.

"ER+ breast cancer can be thought of as a chronic disease because patients generally take estrogen-lowering agents for many years after surgery to repress recurrence," Ellis says. "In other chronic diseases, such as hypertension or diabetes, a patient's response to treatment is continually monitored. But we've never done that with breast cancer. By treating breast cancer patients with estrogen-lowering drugs for three or four months before surgery, we can monitor treatment response and then specifically tailor surgical and post-surgical treatment based on this response."


'/>"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University in St. Louis
Source:Eurekalert  

Related medicine news :

1. Long-term use of anti-anxiety drugs continues in B.C. despite known health risks: UBC study
2. IVF, Fertility Drugs Might Boost Autism Risk
3. System that predicts protein structures could help researchers design drugs
4. Euthanasia and the use of end-of-life drugs without explicit request
5. U.S. FDA Adds 25 New Firms to Import Alert for Promotion of Unapproved New Drugs According to FDAImports.com, LLC
6. Pharmaceutical companies provide EPA 100 drugs to help predict toxicity
7. Bone Drugs Not Linked to Rare Fractures
8. Impotence Drugs May Aid Brain Tumor Treatment
9. Monitoring and control can limit side effects of promising cancer drugs
10. Parkinsons Drugs Tied to Compulsive Behaviors
11. Stomach Acid Drugs Come with Dangers, Studies Show
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Estrogen-lowering drugs minimize surgery in breast cancer patients
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Gevir, a ... deer antler velvet, announced its products are coming soon to Amazon.com, the world’s largest ... Shelley Thomson as a means to develop an effective natural treatment for Shelley’s Multiple ...
(Date:2/22/2017)... ... February 22, 2017 , ... The Waismann Method® is providing a ... have recently fallen victim to America’s opioid epidemic. Now, opiate dependent individuals can be ... are free from the shame, stigma, and harmful labeling believed to prevent ...
(Date:2/22/2017)... ... February 22, 2017 , ... The National Academy of Certified ... the April 2017 testing period. NACCM, a nonprofit organization, has provided the premier ... exam is periodically re-calibrated to ensure that newly certified professionals are prepared to ...
(Date:2/22/2017)... N.J. (PRWEB) , ... February 22, 2017 , ... ... a one-size-fits-all approach, leads to fewer trips the emergency room, fewer hospital admissions, ... The American Journal of Managed Care® (AJMC®) finds. The study can be found ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, ... or not filling a prescription because they could not afford to pay for ... medications were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... -- a condition where an organ of the ... weak abdominal wall. Hernia is classified into five ... hernia, umbilical hernia, and other (hiatal hernia and ... performed using a mesh, made-up of biological or ... the available options, open tension-free repair procedures and ...
(Date:2/22/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), today announced ... ended December 31, 2016. ... This news release should be read ... discussion and analysis for the years ended December 31, 2016 ... available at www.sedar.com and on the Company,s website ...
(Date:2/22/2017)... Feb. 22, 2017 astic drugs develop from ... antineoplastic drug aiming at functions at multiple links. Research ... a new stage. Download the full report: ... nearly four million cases of new tumors in ... population, environmental pollution caused by industrialization and lifestyles changed ...
Breaking Medicine Technology: